SCHEMBL23501460

SCHEMBL23501460

CC(C)[Si](OCCc1ccc(CC(=O)O)cc1)(C(C)C)C(C)C

nearest known ligand 0.53

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ALDH1A1 P00352 2/20 0.53
HPGD P15428 1/20 0.53
HSD17B10 Q99714 1/20 0.53
CA2 P00918 1/20 0.43
CAMK2A Q9UQM7 1/20 0.43
AKR1B1 P15121 1/20 0.41
ABCC4 O15439 1/20 0.41
LMNA P02545 1/20 0.41
GAA P10253 1/20 0.41
TSHR P16473 1/20 0.41
PTGS1 P23219 1/20 0.41
HTT P42858 1/20 0.41
CYP4F2 P78329 2/20 0.40
CYP4A11 Q02928 2/20 0.40
LTB4R Q15722 4/20 0.39
LTB4R2 Q9NPC1 4/20 0.39
TBXAS1 P24557 1/20 0.39
KLKB1 P03952 1/20 0.39
CTSB P07858 1/20 0.39
QPCT Q16769 1/20 0.39

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL23501363 0.86 ALDH1A1 (0.37) ALDH1A1HPGDHSD17B10TSHRCYP4F2
SCHEMBL23501241 0.84 CYP4F2 (0.57) ALDH1A1LMNAGAATSHRCYP4F2
SCHEMBL23501260 0.83 CA2 (0.50) ALDH1A1HPGDHSD17B10CA2CAMK2A
SCHEMBL16245932 0.80 RAB9A (0.47) ALDH1A1HPGDGAAPOLB
SCHEMBL29183695 0.80 ESR1 (0.46) ALDH1A1HSD17B10CA2LMNAPTGS1
SCHEMBL15033738 0.77 POLB (0.46) ALDH1A1HPGDHSD17B10CA2CAMK2A
SCHEMBL6596310 0.76 TAAR1 (0.41) LMNA
SCHEMBL23501267 0.76 CYP4A11 (0.54) ALDH1A1LMNAGAACYP4F2CYP4A11
SCHEMBL30283005 0.75 ALDH1A1 (0.53) ALDH1A1HPGDHSD17B10CA2CAMK2A
SCHEMBL23927618 0.74 FFAR1 (0.51) ALDH1A1LMNAKDM4E

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-112979675-B Small molecular sulfur-containing heterocyclic compound 维眸生物科技(上海)有限公司 2023-12-19 CN disclosed
US-20220332726-A1 NITROXIDE DERIVATIVE OF ROCK KINASE INHIBITOR VIVAVISION (SHANGHAI) LTD (CN) 2022-10-20 US disclosed
EP-3901156-A1 NITROOXYDERIVATIVE OF ROCK KINASE INHIBITOR Vivavision (Shanghai) Ltd (CN) 2021-10-27 EP disclosed
CN-111217834-B Nitroxide derivatives of ROCK kinase inhibitors 维眸生物科技(上海)有限公司 2021-10-26 CN disclosed
CN-112979675-A Small-molecule sulfur-containing heterocyclic compound 维眸生物科技(上海)有限公司 2021-06-18 CN disclosed
WO-2021115495-A1 SMALL-MOLECULE SULFUR-CONTAINING HETEROCYCLIC COMPOUND 维眸生物科技(上海)有限公司 2021-06-17 WO disclosed
CN-111217834-A Nitroxide derivatives of ROCK kinase inhibitors 维眸生物科技(上海)有限公司 2020-06-02 CN disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20220332726-A1 NITROXIDE DERIVATIVE OF ROCK KINASE INHIBITOR ROCK1, NOS1, ROCK2 ALDH1A1 3959/4885HPGD 349/4885HSD17B10 1945/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.